Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Top Stories

Posted By Uma Rajagopal

Posted on December 5, 2024

Novartis cannot block generic of best-selling heart drug, US appeals court says

By Blake Brittain

(Reuters) – Novartis failed to persuade a U.S. appeals court on Wednesday to halt MSN Pharmaceuticals’ proposed generic of Novartis’ blockbuster heart drug Entresto.

The U.S. Court of Appeals for the Federal Circuit upheld a Delaware federal judge’s August decision that found Novartis failed to prove it was likely to win a patent lawsuit against MSN over the drug, removing a roadblock for MSN’s launch of what would be the first U.S. Entresto generic.

Novartis said in a statement that it disagrees with the ruling and is “considering all available options to vigorously defend our intellectual property rights, including further appellate options.”

Spokespeople and attorneys for MSN did not immediately respond to a request for comment.

Entresto is Switzerland-based Novartis’ best-selling drug, bringing the company more than $6 billion in revenue last year. MSN’s version of Entresto was approved by the U.S. Food and Drug Administration in July.

Novartis sued MSN and others seeking to launch Entresto generics in Delaware federal court in 2022 for allegedly infringing a patent that expires in 2026. It requested a preliminary injunction after the FDA’s approval that would block MSN from launching its generic during the case, which is set to go to trial on Monday.

U.S. District Judge Richard Andrews rejected Novartis’ request in August, ruling that it was not sufficiently likely to win on its infringement claims to justify the injunction. The judge paused MSN’s launch of its proposed generic while Novartis appealed to the Federal Circuit.

The Washington-based appeals court affirmed Andrews’ decision on Wednesday and said it saw “no clear error in the district court’s analysis.”

(Reporting by Blake Brittain in Washington; Editing by Richard Chang and Jonathan Oatis)

Recommended for you

  • Enhancing Retail Banking Services Through Sentiment Analysis of Customer Feedback

  • Analyzing Mobile Banking Usage Patterns to Enhance Retail Customer Experience and Engagement

  • Industry 4.0 and Digital Transformation: Enhancing Operational Efficiency in Manufacturing